

Simavita

2019 Annual General Meeting Presentation

November 26, 2019

Sydney, Australia – Simavita Limited (“Simavita” or the “Company”) (ASX: SVA) is pleased to release the attached presentation which will be delivered by its Chairman, Mr Michael Spooner, at the Company’s 2019 Annual General Meeting to be held at 11.00 am this morning at the offices of K&L Gates, 1 O’Connell Street, Sydney NSW 2000.

For further information, please visit the Company’s profile on SEDAR (www.sedar.com) or the Company’s website (www.simavita.com) or contact the persons listed below.

Ms Peta Jurd
Chief Commercial Officer

E: pjurd@simavita.com
T: +61 421 466 653
W: Investor Centre: [Click here](#)

About Simavita

Simavita (ASX: SVA) is a MedTech Company focused on the development of smart, wearable and disposable platform technologies for the health care market.

Our key platform Smartz™ (formerly AlertPLUS™) is a highly disruptive technology focused on transforming a traditional “dumb” diaper into a smart device to help parents and carers of both infants and adults.

With the support of our CDI holders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. www.simavita.com

Forward-Looking Information

This document may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information.

Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita's interim and annual financial statements and management's discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information



Disrupting a US\$64_{bn} global market

Annual General Meeting

26 November 2019

FORWARD LOOKING STATEMENTS

This presentation may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct. In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information.

Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended.

Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.

INTRODUCING




Making Diapers SMART and CONNECTED




[Click here to view video on Smartz](#)

Smartz™ ready
for immediate
market launch




RAPID TRAJECTORY

- We've listened to the market
- Technology driven
- Fast implementation
- Major partners in EU & US



OUR BUSINESS MODEL

- License & royalty income
- Revenue from sale of data
- High margin
- No manufacturing
- No inventory



Global Diaper Market Dynamics

US\$64bn
annual sales

	Value	Volume
	US\$53bn	212bn
	US\$11bn	27bn

RETAILERS

Sales measured in sq feet

Drive Customer loyalty
Store front + online



Diaper Industry:
>200M
people daily

CONSUMER DEMAND

Cheaper
Greater Utility
No longer brand driven
Environmental concerns

MANUFACTURERS

Commodity market
Highly competitive
Reduced margins, > costs
Differentiation is essential



Online sales ↑



Margins ↓

Only marginal change in
product functionality
during past 25yrs

Environmental Impact
>200 years
to decompose

“Industry giants KC and P&G slash costs to maintain margins...”

“Battle among technology giants to capture consumers as Google buys Fitbit...”

“The Royal Commission’s Interim Report into Aged Care is shocking, disturbing heartbreaking...” *Aust PM*

The smart diaper wars
have truly begun...



Procter & Gamble



Kimberly Clarke

Competitive positioning



Company	Abena Nova	Lumi by Pampers	Monit X Huggies	Empowered by Smartz™
Cost?	High cost per item	High acquisition cost	High acquisition cost	Low acquisition cost & cost per item
Adult & Infant?	✗	✗	✗	✓
Everyday use?	✓	✓	✓	✓
Comprehensive functionality?	✗	✗	✗	✓
Tailored to customer	✗	✗	✗	✓
No impact on Diaper Manufacturing?	✗	✗	✓	✓
Urine	✓	✓	✓	✓
Granted IP?	✗	?	?	✓
Independent / Brand neutrality	✗	✗	✗	✓

Smartz™ competitive edge

Rapid commercialization
platform



- NO change to manufacturing equip or efficiency
- Platform independent
- Adult and infant
- GUI specific for major users
- Hyper low cost of manufacturing <1c
- “Plug and Play” ease of use
- Cloud based
- Machine learning
- Standards compliant & safe

Smartz™
addressing the demand
for change



- Real wellness outcomes
- Informed health decisions
- Environmentally better
- Reduced costs
- Efficiency improvements
- Product differentiation
- Speed to market
- Customer loyalty
- Market data
- Reduced inventory levels

What users are saying about Smartz™



- Accurate
- Ease of use
- We're confident using Smartz™
- Clip on POD easy and convenient
- No significant need for training
- Drives real efficiencies
- Materially less soiled clothing and bed linen
- People want to continue using the product

Strong IP position




IP fields include:

- 12 patent families with significant independent claims
- 46 international granted patents
- A further 35 filed & in progress
- Landscape monitoring


- Wearable Sensors
- Algorithms
- Incontinence management software + methods
- Manufacturing methods

GRANTED PATENTS IN TARGET MARKETS



Our Immediate Goal is to
Drive Revenue

Our 2019 drive to revenue - Smartz™ is ready to commercialise



June 2019


Market Assessment



Real demand in all markets




Large manufacturers – product ready



Large distribution channels in place



Immediate focus on Australian Gov
for aged care



The Opportunity

The Smartz™ Opportunity:



- ① A technology platform delivering multiple and significant revenue opportunities
- ② Truly industry disruptive technology
- ③ Low recurring cost model, no manufacturing, no inventory
- ④ Addresses market need for a better environmental solution
- ⑤ Management team with extensive international experience
- ⑥ Extensive IP portfolio of international granted patents

***“Disruptive technologies...
force companies to alter
the way they approach
their business, risk
losing market share or
becoming irrelevant”***

Thank You.

